Vimarsana
Biggest News Aggregation in the World

Page 15 - Immunic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Today - Breaking & Trending Today

EQS-News: Immunic to Participate in Investor and Scientific Conferences in November and December - Vimarsana News

EQS-News: Immunic to Participate in Investor and Scientific Conferences in November and December

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in November and December 10.11.2022 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Investor and Scientific Conferences ...

Immunic to Participate in Investor and Scientific Conferences in November and December - Vimarsana News

Immunic to Participate in Investor and Scientific Conferences in November and December

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

EQS-News: Immunic, Inc.: Immunic to Participate in Investor and Scientific Conferences in November and December - Vimarsana News

EQS-News: Immunic, Inc.: Immunic to Participate in Investor and Scientific Conferences in November and December

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in November and December 10.11.2022 / 12:30 CET/CEST The issuer is solely

Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate - Vimarsana News

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...